A Professional Service Provider for the Pharma Industry
First, a reminder where the name ‘Berger’s disease’ or Morbus Berger comes from. It was Jean Berger, a French pathologist and doctor, who initially identified IgA deposits on the glomeruli of nephritic patients. This was not so long ago; his publication (in French) dates from 1968.[1] Now the race is heating Continue reading COMPARISON OF BAFF / APRIL INHIBITORS
In today’s blog we will share our thoughts about a recent NEJM article, entitled “A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus”.[1] Publications on SLE literally come with a book of abbreviations and definitions nowadays and are not an easy Sunday reads. Of course, there is extensive literature Continue reading TELITACICEPT IN SLE
As many in the field have said before, what we really need are antifungals with a truly novel MoA, not minor changes to well-established classes.[1] There is a shortage of new antifungals for invasive disease. Small improvements in PK will hardly move the field forward or excite investors to engage. Our current Continue reading The Antifungal Landscape – 2